首页> 外文期刊>Antimicrobial agents and chemotherapy. >Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India
【24h】

Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India

机译:印度德里德里胸部医院监测的伏立康唑抗性曲霉临床分离株的多重耐药机制研究

获取原文
获取原文并翻译 | 示例
           

摘要

Invasive and allergic infections by Aspergillus flavus are more common in tropical and subtropical countries. The emergence of voriconazole (VRC) resistance in A. flavus impacts the management of aspergillosis, as azoles are used as the first-line and empirical therapy. We screened 120 molecularly confirmed A. flavus isolates obtained from respiratory and sinonasal specimens in a chest hospital in Delhi, India, for azole resistance using the CLSI broth microdilution (CLSI-BMD) method. Overall, 2.5% (n = 3/120) of A. flavus isolates had VRC MICs above epidemiological cutoff values ( 1 mu g/ml). The whole-genome sequence analysis of three non-wild-type (WT) A. flavus isolates with high VRC MICs showed polymorphisms in azole target genes (cyp51A, cyp51B, and cyp51C). Further, four novel substitutions (S196F, A324P, N423D, and V465M) encoded in the cyp51C gene were found in a single non-WT isolate which also exhibited overexpression of cyp51 (cyp51A, -B, and -C) genes and transporter genes, namely, MDR1, MDR2, atrF, and mfs1. The homology model of the non-WT isolate suggests that substitutions S196F and N423D exhibited major structural and functional effects on cyp51C drug binding. The substrate (drug) may not be able to bind to binding pocket due to changes in the pocket size or closing down or narrowing of cavities in drug entry channels. Notably, the remaining two VRC-resistant A. flavus isolates, including the one which had a pan-azole resistance phenotype (itraconazole and posaconazole), did not show upregulation of any of the analyzed target genes. These results suggest that multiple target genes and mechanisms could simultaneously contribute to azole resistance in A. flavus.
机译:在热带和亚热带的国家,曲霉和患有患者的侵袭性和过敏性感染更为常见。 A.FlaVus抗性的伏立康唑(VRC)抗性的出现会影响曲霉病的管理,因为唑类用作一线和经验治疗。我们筛查120分子证实的A.使用CLSI肉汤微量稀释(CLSI-BMD)方法,从德里德里的胸部医院中获得的呼吸系统和Sinonasal标本中获得的黄色病毒分离物。总体而言,2.5%(n = 3/120)的A. flavus分离物具有高于流行病学截止值(&1μg/ ml)的VRC MIC。具有高VRC MIC的三种非野生型(WT)A.的全基因组序列分析。唑族靶基因(CYP51A,CYP51B和CYP51C)中的多态性显示出多态性。此外,在CYP51C基因中编码的四种新的取代(S196F,A324P,N423D和V465M)在单个非WT分离物中发现,该非WT分离物也表现出CYP51(CYP51A,-B和-C)基因和转运基因的过表达,即,MDR1,MDR2,ATRF和MFS1。非WT分离物的同源模型表明取代S196F和N423D对CYP51C药物结合具有主要的结构和功能作用。由于口袋尺寸的变化或在药物入口通道中的空腔关闭或缩小,基板(药物)可能无法与结合口袋结合。值得注意的是,剩余的两种抗性A.意大利分离物,包括具有泛邻唑抗性表型(Itraconazole和Posaconazole)的抗性分离物未显示出任何分析的靶基因的上调。这些结果表明,多种靶基因和机制可以同时有助于A.Flavus中的唑抗性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号